Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$1.61 USD
-0.12 (-6.94%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Adial Pharmaceuticals, Inc. [ADIL]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat on EPS 4Q23 - reiterate Buy rating and $8 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, update ahead of 4Q23 results - reiterate Buy rating and $8 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat 2Q23 EPS by $0.99 - reiterate Buy rating and establishing an $8 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat 1Q23 EPS by $0.03 - reiterate Buy rating and $6 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat 4Q22 EPS by $0.05 - reiterate Buy rating, but lowering PT to $6 from $9
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Business update yesterday shows positive data for its alcohol use disorder drug to achieve FDA approval - reiterate Buy rating and $9 PT.
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sees path for its alcohol use disorder drug to achieve FDA approval - reiterate Buy rating and $9 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat 3Q22 EPS by $0.06 - reiterate Buy rating and $9 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, beat 2Q22 EPS by $0.01 - reiterate Buy rating but lowering PT to $9 from $15
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, reports promising clinical results - reiterate Buy rating and $15 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 EPS by $0.04 - reiterate Buy rating and $15 PT
Provider: Litchfield Hills Research, LLC
Analyst: Research Department
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma, Adial, adj. operating results beat EPS by $0.01 - reiterate Buy rating and $15 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biopharma Adial reports in-line 3Q21 - reiterate Buy rating and $15 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Genetic targeting for treating AUD to show efficacy and longterm potential-Initiating Coverage
Provider: Quantum Research Group, LLC
Analyst: Research Department
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adial Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiate at Buy Rating with Treatment for AUD
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WERTHER C
|